Read by QxMD icon Read

Diabetes Technology & Therapeutics

Maria Ida Maiorino, Giuseppe Bellastella, Ofelia Casciano, Paolo Cirillo, Vittorio Simeon, Paolo Chiodini, Michela Petrizzo, Maurizio Gicchino, Ornella Romano, Paola Caruso, Dario Giugliano, Katherine Esposito
BACKGROUND: Type 1 diabetic patients have high instability of daily glucose levels. The aim of this study was to evaluate the long-term effects of continuous subcutaneous insulin infusion (CSII) therapy, compared with multiple daily injections of insulin (MDI), on glucose variability, in young type 1 diabetic patients transitioned to the adult diabetes care. METHODS: Patients aged 18-30 years and considered eligible for insulin pump therapy were included in the study...
January 5, 2018: Diabetes Technology & Therapeutics
David L Levitt, Elias K Spanakis, Kathleen A Ryan, Kristi D Silver
BACKGROUND: Insulin pumps and continuous glucose monitoring (CGM) are commonly used by patients with diabetes mellitus in the outpatient setting. The efficacy and safety of initiating inpatient insulin pumps and CGM in the nonintensive care unit setting is unknown. MATERIALS AND METHODS: In a prospective pilot study, inpatients with type 2 diabetes were randomized to receive standard subcutaneous basal-bolus insulin and blinded CGM (group 1, n = 5), insulin pump and blinded CGM (group 2, n = 6), or insulin pump and nonblinded CGM (group 3, n = 5)...
January 2, 2018: Diabetes Technology & Therapeutics
Fumi Uemura, Yosuke Okada, Keiichi Torimoto, Yoshiya Tanaka
BACKGROUND: To determine the factors associated with hypoglycemia in patients with type 2 diabetes mellitus (T2DM) on insulin therapy. METHODS: This retrospective study included 62 inpatients with T2DM on insulin therapy who underwent 5-day continuous glucose monitoring (CGM). We analyzed the relation between hypoglycemia (defined as blood glucose below 70 mg/dL, as determined by the CGM) and time spent in hypoglycemia with fasting blood glucose, mean blood glucose (MBG), standard deviation (SD), coefficient of variation, minimum blood glucose level, maximum blood glucose level, and the percent time spent with blood glucose levels of >180 mg/dL...
January 2, 2018: Diabetes Technology & Therapeutics
Andrzej Gawrecki, Dorota Zozulinska-Ziolkiewicz, Bartlomiej Matejko, Jerzy Hohendorff, Maciej T Malecki, Tomasz Klupa
In this brief report, we describe the feat of four men with type 1 diabetes mellitus (T1DM) who decided to take part in a mountain ultramarathon in Bieszczady, Poland on May 27, 2016. Before participating in the competition, they asked two diabetologists for a consultation and to assist in diabetic control during the marathon. The aim of the study was to assess the metabolic safety in people with T1DM during extreme physical exertion in a mountain ultramarathon. All subjects were treated with continuous subcutaneous insulin infusion...
January 2, 2018: Diabetes Technology & Therapeutics
Giada Acciaroli, Martina Vettoretti, Andrea Facchinetti, Giovanni Sparacino
BACKGROUND: Continuous glucose monitoring (CGM) sensors need to be calibrated twice/day by using self-monitoring of blood glucose (SMBG) samples. Recently, to reduce the calibration frequency, we developed an online calibration algorithm based on a multiple-day model of sensor time variability and Bayesian parameter estimation. When applied to Dexcom G4 Platinum (DG4P) sensor data, the algorithm allowed the frequency of calibrations to be reduced to one-every-four-days without significant worsening of sensor accuracy...
December 21, 2017: Diabetes Technology & Therapeutics
Agnieszka Szadkowska, Andrzej Gawrecki, Arkadiusz Michalak, Dorota Zozulińska-Ziółkiewicz, Wojciech Fendler, Wojciech Młynarski
BACKGROUND AND AIMS: To evaluate the clinical accuracy of a flash glucose monitoring device FreeStyle Libre (FSL) among children with type 1 diabetes in real-world settings during a summer camp. MATERIALS AND METHODS: During a summer camp, children with type 1 diabetes (n = 79, aged 8-18 years) were provided with FSLs for 12 days. On days 3, 7, and 11 of the study, they underwent supervised glucose testing at 8 timepoints. Glycemia was estimated by using FSL and measured with a personal glucometer within a period of 2 min...
December 13, 2017: Diabetes Technology & Therapeutics
Karl-Michael Derwahl, Timothy S Bailey, Karin Wernicke-Panten, Lin Ping, Suzanne Pierre
BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog®; Ly-Lis). This study aimed to show similar efficacy, safety, and immunogenicity of SAR-Lis versus Ly-Lis in adult patients with type 2 diabetes mellitus (T2DM) treated with multiple daily injections, while using insulin glargine (GLA-100; Lantus®) as basal insulin. METHODS: SORELLA 2 was a 6-month, randomized, open-label, Phase 3 study (NCT02294474). Insulin doses were adjusted to achieve fasting and 2-h postprandial glucose targets according to American Diabetes Association guidelines...
December 12, 2017: Diabetes Technology & Therapeutics
Sam Matthew Pearson, Ramzi A Ajjan
No abstract text is available yet for this article.
December 12, 2017: Diabetes Technology & Therapeutics
Thomas A Peyser, Andrew K Balo, Bruce A Buckingham, Irl B Hirsch, Arturo Garcia
BACKGROUND: High levels of glycemic variability are still observed in most patients with diabetes with severe insulin deficiency. Glycemic variability may be an important risk factor for acute and chronic complications. Despite its clinical importance, there is no consensus on the optimum method for characterizing glycemic variability. METHOD: We developed a simple new metric, the glycemic variability percentage (GVP), to assess glycemic variability by analyzing the length of the continuous glucose monitoring (CGM) temporal trace normalized to the duration under evaluation...
December 11, 2017: Diabetes Technology & Therapeutics
Elizabeth Burner, Chun Nok Lam, Rebecca DeRoss, Marjorie Kagawa Singer, Michael Menchine, Sanjay Arora
BACKGROUND: Social support interventions can improve diabetes self-care, particularly for Latinos, but are time and resource intensive. Mobile health may overcome these barriers by engaging and training supporters remotely. METHODS: We conducted a randomized controlled feasibility trial of emergency department patients with diabetes to determine the feasibility of enrolling patients and supporters, acceptability of the intervention, and preliminary efficacy results to power a larger trial...
December 11, 2017: Diabetes Technology & Therapeutics
Rudolf Chlup, Sarah Runzis, Javier Castaneda, Scott W Lee, Xuan Nguyen, Ohad Cohen
BACKGROUND: This prospective single-center study recruited insulin-resistant continuous subcutaneous insulin infusion (CSII) therapy-naive patients with type 2 diabetes (T2D) using insulin analog-based multiple daily injections (MDI) therapy and metformin. METHODS: A total of 23 individuals with T2D (70% male), aged a mean ± standard deviation 57.2 ± 8.03 years, with body mass index of 36.2 ± 7.02 kg/m2, diabetes duration of 13.3 ± 4.64 years, and HbA1c of 10...
December 7, 2017: Diabetes Technology & Therapeutics
Michelle L Litchman, Nancy A Allen, Vanessa D Colicchio, Sarah E Wawrzynski, Kerri M Sparling, Krissa L Hendricks, Cynthia A Berg
BACKGROUND: Little research exists regarding how real-time continuous glucose monitoring (RT-CGM) data sharing plays a role in the relationship between patients and their care partners. OBJECTIVE: To (1) identify the benefits and challenges related to RT-CGM data sharing from the patient and care partner perspective and (2) to explore the number and type of individuals who share and follow RT-CGM data. METHODS: This qualitative content analysis was conducted by examining publicly available blogs focused on RT-CGM and data sharing...
November 20, 2017: Diabetes Technology & Therapeutics
Toni L Cordero, Satish K Garg, Ronald Brazg, Timothy S Bailey, John Shin, Scott W Lee, Francine R Kaufman
A 3-month pivotal trial using the MiniMed™ 670G hybrid closed-loop (HCL) system in adolescent and adult patients with type 1 diabetes (T1D), relative to a 2-week baseline run-in period, resulted in increased sensor glucose (SG) values in target range (71-180 mg/dL), reduced HbA1c levels, and no events of diabetic ketoacidosis or severe hypoglycemia ( : NCT02463097). This brief report evaluated how prior continuous glucose monitoring (CGM) experience influenced glycemic outcomes, in the same pivotal trial...
November 17, 2017: Diabetes Technology & Therapeutics
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Warsaw, Poland, for the 10th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts to facilitate new collaborations and research projects that can improve the lives of people with diabetes. The 2017 meeting comprised a comprehensive scientific program, parallel interactive workshops, and four keynote lectures.
November 14, 2017: Diabetes Technology & Therapeutics
Jill Weissberg-Benchell, Danielle Hessler, Lawrence Fisher, Steven J Russell, William H Polonsky
OBJECTIVES: The study assessed the psychosocial impact of the bihormonal bionic pancreas (BP) on adults in a real-world outpatient setting. RESEARCH DESIGN AND METHODS: Thirty-nine adults with type 1 diabetes at four study centers across the U.S. participated in a two-arm, random-order, crossover design study: 11 days with the BP and 11 days with their usual care (UC). Psychosocial questionnaires were administered before the first study arm, at the end of the first study arm, and at the end of the second study arm...
November 6, 2017: Diabetes Technology & Therapeutics
Anoop Misra, Rupali Mukherjee, Atul Luthra, Padam Singh
No abstract text is available yet for this article.
November 1, 2017: Diabetes Technology & Therapeutics
Jordan E Pinsker, Benjamen E Schoenberg, Colleen Garey, Asher Runion, Arianna Larez, David Kerr
We sought to determine the real-life experiences of individuals traveling long distance (across five or more time-zones) with type 1 diabetes (T1D). Five hundred three members of the T1D Exchange online community ( ) completed a 45-question survey about their travel experiences flying long distance. The cohort was stratified by duration of T1D and whether or not participants used continuous subcutaneous insulin infusion (CSII) therapy and/or a continuous glucose monitor (CGM). In the last 5 years, 71% of participants had flown long distance...
October 27, 2017: Diabetes Technology & Therapeutics
Claudio Cobelli, Andrea Facchinetti
No abstract text is available yet for this article.
January 2018: Diabetes Technology & Therapeutics
Arturo Garcia, Andrew K Balo, Bruce A Buckingham, Irl B Hirsch, Thomas A Peyser
BACKGROUND: The problem of glycemic variability has been widely acknowledged in patients with diabetes with severe insulin deficiency. In a companion article, we proposed a novel metric, the glycemic variability percentage (GVP), for assessing glycemic variability that accounts for both the amplitude and frequency of glycemic fluctuations. METHOD: We applied the new metric, the GVP, to a previously reported case of a subject using an earlier generation continuous glucose monitoring (CGM) device, in which successive periods of use were associated with an apparent decrease in glycemic variability...
December 2017: Diabetes Technology & Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
December 2017: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"